NeurologyLive® Mind Moments®

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona, spoke about the emerging commotion around cell therapies as a way to treat patients with epilepsy. The discussion, which took place at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, California, covers the thought process behind this approach and why it may hold greater advantages over other traditional surgeries that result in detrimental cognitive effects. Parker, director of the Device-Based Neuroelectronics Lab, spoke on the different types of cell therapies currently in development, the limitations and challenges associated with these medications, and the need to create innovative trials to appropriately test them. Furthermore, Parker spoke on the therapeutic pipeline of cell therapies for epilepsy, including his experience leading a study site for a first-in-human trial of an investigational agent NRTX-1001, a product derived from human pluripotent stem cells. Looking for more epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:00 – Idea behind cell therapy to treat epilepsy 4:05 – Current state of stem cell therapies for neurological disorders, focusing on Parkinson disease, stroke, and epilepsy 8:05 – NTE001 study of NRTX-1001, an investigational human embryonic stem cell product 11:45 – Neurology News Minute 13:50 – Unanswered questions and safety concerns with cell therapies; challenges with clinical trial design and the need for more innovative trials 17:35 – Misconceptions or gaps in understanding about cell therapies for epilepsy 20:05 – Unique challenges and potential of stem cell therapies for epilepsy, particularly in younger patients; patient motivation and hope The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Anavex Submits Marketing Authorization Application for Blarcamesine in Alzheimer Disease in the EU Testing Begins for RELIEV-CM2 Study of ShiraTronics Neuromodulation Device in Chronic Migraine STK-001 Gains FDA Breakthrough Designation as Potential Disease-Modifying Treatment for Dravet Syndrome Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Andy Berkowski, MD, PhD, founder of Relax Health, sat down to discuss the American Academy of Sleep Medicine's (AASM) recently published guideline update for the treatment of restless legs syndrome (RLS). Berkowski, who serves as a vice chair of the AASM's Practice Guidelines Task Force, provided clinical insight on the reasons behind the guidelines, pointing to the vast research advances and literature updates since its last iteration in 2012. Additionally, he touched on the greatest changes to the guidelines, noting things like the shift away from dopaminergic agents, the importance of iron in RLS pathophysiology, and the use of alpha-2-delta ligands and intravenous iron as first-line treatments. Berkowski also shared thoughts on how the guidelines impact care for patients of all ages, sexes, and RLS subtypes, as well as some of the more troubling parts of the guidelines to write and areas that were left unanswered. Furthermore, he gave his thoughts on how these guidelines will transform care going forward, including accelerating conversations on preventing RLS in many cases in the near future. Looking for more sleep disorder discussion? Check out the NeurologyLive® Sleep disorders clinical focus page. Episode Breakdown: 1:00 – Reasons behind new guidelines, progress in clinical research 2:50 – Overview of the greatest changes to the guidelines and what treating physicians should key in on 11:25 – Neurology News Minute 13:40 – How the guidelines address management based on age, sex, and RLS subtype 16:30 – Challenges when drafting the guidelines and the unanswered questions that remain 20:10 – A promising future for treating, managing, and preventing RLS The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Neurogene Reports Serious Adverse Event in Phase 1/2 Rett Study of Gene Therapy NGN-401 Huntington Agent SAGE-718 to be Discontinued Following Disappointing Phase 2 DIMENSION Trial Results Alzheimer Agent Simufilam Fails to Meet Primary End Point in Phase 3 Study Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Lara Jehi, MD, MHCDS, an epilepsy specialist and Cleveland Clinic’s Chief Research and Information Officer, sat down to discuss a recently published study that explored using machine learning algorithms to predict seizure control after epilepsy surgery. In the interview, Jehi explained the unique aspects of the study design, emphasizing the importance of a large, well-characterized patient cohort with consistent follow-up and the choice of scalp EEG—a commonly used, non-invasive test in epilepsy care—as the data source. In addition, Jehi touched on the use of AutoML to streamline the process, enabling efficient identification of the top-performing algorithms and enhancing the model’s predictive accuracy. Furthermore, she spoke on the team needed to properly implement machine learning techniques for neurosurgery, while providing recommendations for other institutions interested in pursuing these types of approaches. Looking for more epilepsy discussion? Check out the NeurologyLive® epilepsy clinical focus page. Episode Breakdown: 1:00 – Background on various machine learning approaches for epilepsy research 3:20 – Study details, findings, and notable takeaways 8:20 – Neurology News Minute 10:20 – Novelty in using scalp EEG and its global application 15:30 – Team personnel needed for proper implementation of machine learning techniques in epilepsy surgery The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy FDA Places Clinical Hold on Epilepsy Agent RAP-219 for Diabetic Peripheral Neuropathic Pain First-Ever CRISPR/Cas13-RNA Editing Therapy to be Tested in Phase 1 Study of Age-Related Macular Degeneration Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Lawrence Robinson, MD, a senior scientist at Sunnybrook Research Institute, sat down to discuss his presentation from the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, focused on educating the next generation of neuromuscular and electrodiagnostic (EDX) practitioners. Robinson gave an overview of his presentation, why this was a topic of interest, and the major differences in how this generation of medical students learn relative to previous ones. In addition, he discussed adapting to new learning styles, the benefits of flipped classrooms, and the impact of technology on education and practice. Furthermore, he touched upon the personal connections and humor in teaching, as well as ways to improve critical evaluation skills as a learner. Looking for more neuromuscular discussion? Check out the NeurologyLive® neuromuscular clinical focus page. Episode Breakdown: 1:05 – Overviewing and background on AANEM presentation 3:15 – Challenges with educating next generation of neuromuscular and EDX practitioners 4:40 – Areas of opportunity and growth for these next generation learners 5:50 – Neurology News Minute 8:00 – Novelty and advantages of flipped classroom approaches to teaching 10:10 – Future expected changes to neuromuscular care 11:55 – Final thoughts on care on NM and EDX education The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Phase 3 ENSURE Program of Vidofludimus Calcium Continues Following Positive Futility Analysis Gene Therapy FLT201 Shows Promise in Early-Stage Study of Gaucher Disease Risk of ARIA-E in Donanemab Attenuated Through New Enhanced Titration Method of Delivery Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this episode, we cover the recent approval of Avadel's sodium oxybate formulation (Lumryz) as a treatment for pediatric patients with narcolepsy aged 7 years and older. The new indication expands on its previous one, granted in May 2023, which included the the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. It's initial approval was based on data from the phase 3 REST-ON trial (NCT02720744), a large-scale study in which the therapy met all 3 of its primary end points of change from baseline in mean sleep latency on the Maintenance of Wakefulness test, Clinical Global Impression Improvement, and weekly cataplexy attacks. Following its new indication, NeurologyLive sat down with Anne Marie Morse, DO, FAASM, a pediatric sleep disorders expert, to discuss the significance of the new approval. Morse, director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital as well as the program director for Child Neurology Residency Program, provided commentary on the clinical considerations behind this once-nightly formulation of sodium oxybate, and how it should be used going forward. For more of NeurologyLive's coverage of sodium oxybate's (Lumryz) expanded indication, head here: FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy Episode Breakdown: 2:10 – Immediate reaction and significance  4:10 – Considerations and caution with prescribing sodium oxybate 8:20 – Closing remarks and the need to utilize highly effective treatments for narcolepsy Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Daniel Claaseen, MD, MS, a professor of neurology and chief of the Behavioral and Cognitive Neurology Division at Vanderbilt University Medical Center, offered his insight on phase 1/2 data that was recently presented at the International Parkinson and Movement Disorder Society (MDS) Congress on ATH434, an investigational drug in development from Alterity Therapeutics for multiple system atrophy (MSA). He dove into the therapy's mechanism of action and the currently known safety profile and considerations for its use, as well as the next steps in advancing care for patients with MSA as a whole. Looking for more movement disorders discussion? Check out the NeurologyLive® movement disorder clinical focus page. Episode Breakdown: 1:10 – Overviewing the conduct of the phase 1/2 studies 3:00 – Notable findings from data presented at MDS 4:30 – Mechanism of action behind ATH434 8:20 – Neurology News Minute 10:20 – Next steps in ATH434's development 11:15 – Current unmet needs for patients with MSA The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Removes Partial Hold for Myotonic Dystrophy Agent AOC 1001 FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, provided an in-depth overview on the newly announced McDonald criteria to diagnose multiple sclerosis (MS). Ontaneda, who also serves as an assistant professor of neurology, discussed the most notable changes to the criteria and how it may help towards improving rates of misdiagnosis and missed diagnosis. He spoke on the incorporation of new biomarkers, such as central vein sign and paramagnetic rim lesions, and the ability to diagnose MS in stages before clinical presentation shows. Furthermore, Ontaneda gave some perspective on the areas of the new criteria that will take some time to adjust to, as well as how these criteria may change the philosophical perspective of the disease as a whole.  Looking for more Multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page. Episode Breakdown: 1:10 – Focus and direction of new diagnostic criteria 3:00 – Overviewing specific changes to McDonald criteria 10:50 – Approach to diagnosing pre-MS; treating radiologically isolated syndrome earlier 12:55 – Neurology News Minute 15:10 – Incorporation of new biomarkers, central vein sign, paramagnetic rim lesions, OCT 21:45 – Unanswered questions/challenges left out of the diagnostic criteria The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Potential Regulatory Submission for Inebilizumab in Myasthenia Gravis Following Positive Phase 3 MINT Data Parkinson Agent Tavapadon Meets Primary and Secondary End Points as Monotherapy in Phase 3 TEMPO-1 Trial Sage Therapeutics and Biogen Officially Announce Ending of SAGE-324 Program in Essential Tremor Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Joanne Donovan, MD, PhD, chief medical officer at Edgewise Therapeutics, sat down to discuss the clinical program of EDG-5506, an investigational drug in development for Becker muscular dystrophy, and the recent progress in treating and understanding Becker muscular dystrophy. She spoke on the mechanism of action of the drug, also known as sevasemten, and why the company believes it can be therapeutically beneficial for this patient population. Furthermore, Donovan spoke on the previous failures in drug development for Becker, advances in biomarker detection, and how other trials paved the way for the company's phase 2 study and open label extension, dubbed CANYON (NCT05291091) and GRAND CANYON. Furthermore, she spoke on the ways the clinical community has tried to improve the quality of life for patients with Becker, focusing on approaches and tactics that curve cardiac issues commonly seen in this group.  Looking for more Neuromuscular discussion? Check out the NeurologyLive® neuromuscular clinical focus page. Episode Breakdown: 1:15 – Overview of CANYON study and extension phase  3:50 – Mechanism of action of EDG-5506 6:30 – How previous trial experiences shaped CANYON  10:10 – Neurology News Minute 11:50 – Ongoing challenges with treating and testing drugs for Becker 15:25 – Safety profile of EDG-5506 16:45 – Ways to tackle cardiac issues in Becker The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Digital Therapeutic CT-132 Meets Primary End Point in Phase 3 Study of Preventive Migraine FDA Supports Alpha-Synuclein Seed Amplification Assay Biomarker for Clinical Trials in Parkinson Disease FDA Approves Subcutaneous Formulation of Ocrelizumab for Relapsing and Progressive Multiple Sclerosis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, epilepsy expert Imad Najm, MD, PhD, sat down to discuss the upcoming Cleveland Clinic Epilepsy Summit, an educational symposium that takes place September 11-15, in Cleveland, Ohio. Najm, who serves as the director of Cleveland Clinic's Epilepsy Center at the Cleveland Clinic Neurological Institute, spoke about the objectives and goals of the meeting, including updates on sEEG, epilepsy surgery, treatments for drug-resistant epilepsy, and gene therapy. In addition, he provided an overview of the latest advances in epilepsy surgery, genetics, and seizure controlling approaches. Furthermore, he spoke on some of the educational challenges with adjusting to changes in neurosurgery, the potential benefits and limitations of gene therapy, and the future of epilepsy treatment.  Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:10 – Mission and goals of Epilepsy Summit  3:05 – Overviewing sessions and educational attainment 4:55 – Changes to epilepsy surgery, advances over the years 9:15 – Neurology News Minute 11:50 – Learning curve for understanding new epilepsy surgery tactics 13:50 – Closing thoughts on the upcoming meeting 15:50 – Potential benefits and challenges to gene therapy for epilepsy The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: EMA Accepts Marketing Authorization Application for Huntington Disease Agent Pridopidine BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 HERCULES Study of Non-Relapsing Secondary Progressive MS FDA Accepts Resubmitted New Drug Application for Migraine Treatment AXS-07 Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Sharon Cohen, MD, a behavioral neurologist, sat down to discuss positive data from an ongoing phase 1 study of mivelsiran (Alnylam Pharmaceuticals), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer disease (AD). Cohen, who also serves as the medical director of the Toronto Memory Program at the University of Toronto, discussed the potential of RNA therapeutics for treating AD, the unique mechanism of action of mivelsiran, and some of the early promising safety, efficacy, and pharmacokinetic data observed in the phase 1 trial. In addition, Cohen touched upon the idea of how RNA therapeutics could be used in combination with previously approved novel treatments and the benefits mivelsiran brings with no observed amyloid-related imaging abnormalities. Furthermore, the discussion covered some of the potential of this investigational agent, what to expect in the multi-dose part B of the study, and an additional phase 2 study in cerebral amyloid angiopathy.  Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive® Alzheimer disease/dementia clinical focus page. Episode Breakdown: 1:15 – Mechanism of action of mivelsiran and how it can be potentially beneficial in AD 4:15 – Growing knowledge of RNA therapeutics and their impact on neurologic conditions 7:00 – Neurology News Minute 10:10 – Phase 1 study data, including efficacy, safety, biomarker, and pharmacokinetic results 19:20 – How mivelsiran fits with other approved therapies for AD; future goals and directions of the drug The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Clears Indapta Therapeutics’ IND for Cell Therapy IDP-023 in Progressive Multiple Sclerosis Muscle-Targeting Therapy Apitegromab Effective in Spinal Muscular Atrophy Over 4 Year Period FDA Approves Medtronic’s Deep Brain Stimulation Technology for Asleep Capabilities Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.